ADC Therapeutics (ADCT) Short term Debt (2020 - 2026)

ADC Therapeutics (ADCT) has reported Short term Debt for 6 consecutive years, with $4.6 million the latest figure, recorded in Q1 2026.

• Quarterly Short term Debt changed N/A year-over-year to $4.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.6 million (changed N/A YoY) and the FY2025 annual result came in at $3.0 million, changed N/A from the prior year.
• Short term Debt climbed to $4.6 million in Q1 2026 per ADCT's latest filing, from $3.0 million in the prior quarter.
• Over the last five years, Short term Debt for ADCT reached as high as $14.3 million in Q3 2023 and fell as low as $3.0 million in Q4 2025.
• A 4-year average of $9.7 million and a median of $12.5 million in 2022 frame the typical range for Short term Debt.
• Annual changes were most pronounced in 2022 — Short term Debt grew 6.14% — and 2023, when it jumped 111.47%.
• Year by year, Short term Debt stood at $12.5 million in 2022, then rose by 14.87% to $14.3 million in 2023, then tumbled by 79.06% to $3.0 million in 2025, then surged by 54.5% to $4.6 million in 2026.
• According to Business Quant data, Short term Debt over the past three periods registered $4.6 million, $3.0 million, and $14.3 million for Q1 2026, Q4 2025, and Q3 2023 respectively.